Amgen

AMGN Healthcare & Pharma 6/10 Medium Risk
6/10
Sector avg: 2.8/10

Amgen carries $54.6B in long-term debt, with $56.0B in scheduled principal maturities. AMGN shows a debt-to-equity ratio of 6.3x — well above the typical threshold for financial stress. DebtCanary scores AMGN at 6/10, indicating moderate refinancing pressure.

Maturity Schedule

Year 1 $4.6B Year 2 $2.7B Year 3 $5.0B Year 4 $2.9B Year 5 $4.0B Beyond 5 $36.8B
Period Amount Due % of Total
Year 1 (0-12 months) $4.6B 8.2%
Year 2 (12-24 months) $2.7B 4.9%
Year 3 (24-36 months) $5.0B 8.9%
Year 4 (36-48 months) $2.9B 5.3%
Year 5 (48-60 months) $4.0B 7.1%
Beyond 5 Years $36.8B 65.7%
Total Scheduled Maturities $56.0B 100.0%

Key Metrics

Total Long-Term Debt
$54.6B
Near-Term (12mo)
$4.6B
Interest Coverage
N/A
Debt/Equity
6.31
Cash Coverage
2.00x
Operating Income
$9.1B
EBITDA
$14.2B
Debt / EBITDA
3.8x

Score Components

Component Value Weight
Near-Term Maturity Concentration 8.2% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 6.31 25%
Cash Coverage of Near-Term Debt 2.00x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-13. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Amgen →